Alnylam's AMVUTTRA Gets Approval In Europe To Treat ATTR Amyloidosis With Cardiomyopathy June 09, 2025 — 07:33 am EDT Written by RTTNews.com for RTTNews -> ...

There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ATTR (wtATTR), which ...

CAMBRIDGE, Mass., June 09, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has ...

There are two different forms of ATTR hereditary ATTR (hATTR), which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ATTR (wtATTR), which occurs ...

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) announced Monday that the European Commission or EC has granted approval for AMVUTTRA (vutrisiran) for the treatment of ...

Shimane Pref. loses out on $123,000 in Japan subsidies due to grant application typo June 7, 2025 (Mainichi Japan) Japanese version ...

BridgeBio is also making strides in clinical research, as they have initiated dosing in the ACT-EARLY trial, a study aimed at preventing transthyretin amyloid disease (ATTR) in asymptomatic carriers.

HELIOS-B investigators randomized 655 patients with ATTR-CM and a clinical history of HF to subcutaneous vutrisiran 25 mg or placebo once every 3 months, with the double-blind period lasting 33 to 36 ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer. The oral ...

CAMBRIDGE, Mass., May 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...